# BLACKBERRY Ltd: financial statements, quarterly

BB · NYSE · CIK 1070235 · [Technology](/sectors/technology.md) · fiscal year ends Feb 28

Pages: [Overview](/companies/bb.md) · [Financials](/companies/bb/financials.md) · [Filings](/companies/bb/filings.md) · [Insiders](/companies/bb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-11-30) | Q4 FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q4 FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q4 FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [152](/filings/0001070235-24-000156.md) | [153 d](/filings/0001070235-26-000039.md) | [123](/filings/0001070235-25-000132.md) | [126](/filings/0001070235-25-000176.md) | [144](/filings/0001070235-25-000198.md) | [142 d](/filings/0001070235-26-000039.md) | [122](/filings/0001070235-26-000076.md) | [130](/filings/0001070235-26-000115.md) | [142](/filings/0001070235-25-000198.md) | [156 d](/filings/0001070235-26-000039.md) | [153](/filings/0001070235-26-000076.md) | [163](/filings/0001070235-26-000115.md) |
| Cost of revenue | $m | [33.0](/filings/0001070235-24-000156.md) | [29.4 d](/filings/0001070235-26-000039.md) | [33.4](/filings/0001070235-25-000132.md) | [37.6](/filings/0001070235-25-000176.md) | [31.4](/filings/0001070235-25-000198.md) | [37.6 d](/filings/0001070235-26-000039.md) | [31.4](/filings/0001070235-26-000076.md) | [33.0](/filings/0001070235-26-000115.md) | [31.9](/filings/0001070235-25-000198.md) | [34.6 d](/filings/0001070235-26-000039.md) | [33.2](/filings/0001070235-26-000076.md) | [36.2](/filings/0001070235-26-000115.md) |
| Gross profit | $m | [119](/filings/0001070235-24-000156.md) | [124 d](/filings/0001070235-26-000039.md) | [90.0](/filings/0001070235-25-000132.md) | [88.6](/filings/0001070235-25-000176.md) | [112](/filings/0001070235-25-000198.md) | [104 d](/filings/0001070235-26-000039.md) | [90.3](/filings/0001070235-26-000076.md) | [96.6](/filings/0001070235-26-000115.md) | [110](/filings/0001070235-25-000198.md) | [121 d](/filings/0001070235-26-000039.md) | [120](/filings/0001070235-26-000076.md) | [127](/filings/0001070235-26-000115.md) |
| Research and development | $m | [29.0](/filings/0001070235-24-000156.md) | [29.1 d](/filings/0001070235-26-000039.md) | [30.6](/filings/0001070235-25-000132.md) | [27.1](/filings/0001070235-25-000176.md) | [27.9](/filings/0001070235-25-000198.md) | [23.2 d](/filings/0001070235-26-000039.md) | [25.0](/filings/0001070235-26-000076.md) | [25.6](/filings/0001070235-26-000115.md) | [29.6](/filings/0001070235-25-000198.md) | [33.4 d](/filings/0001070235-26-000039.md) | [33.0](/filings/0001070235-26-000076.md) | [33.2](/filings/0001070235-26-000115.md) |
| Selling, general and administrative | $m | [85.0](/filings/0001070235-23-000165.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [18.0](/filings/0001070235-24-000156.md) | [(14.0) d](/filings/0001070235-26-000039.md) | [(12.9)](/filings/0001070235-25-000132.md) | [2.2](/filings/0001070235-25-000176.md) | [19.5](/filings/0001070235-25-000198.md) | [(8.0) d](/filings/0001070235-26-000039.md) | [2.0](/filings/0001070235-26-000076.md) | [11.5](/filings/0001070235-26-000115.md) | [11.9](/filings/0001070235-25-000198.md) | [22.9 d](/filings/0001070235-26-000039.md) | [15.3](/filings/0001070235-26-000076.md) | [33.6](/filings/0001070235-26-000115.md) |
| Income tax | $m | [15.0](/filings/0001070235-24-000156.md) | [4.2 d](/filings/0001070235-26-000039.md) | [7.6](/filings/0001070235-25-000132.md) | [1.4](/filings/0001070235-25-000176.md) | [6.6](/filings/0001070235-25-000198.md) | [1.4 d](/filings/0001070235-26-000039.md) | [3.0](/filings/0001070235-26-000076.md) | [0.1](/filings/0001070235-26-000115.md) | [1.1](/filings/0001070235-25-000198.md) | [1.6 d](/filings/0001070235-26-000039.md) | [7.9](/filings/0001070235-26-000076.md) | [1.3](/filings/0001070235-26-000115.md) |
| Net income | $m | [(21.0)](/filings/0001070235-24-000156.md) | [(56.2) d](/filings/0001070235-26-000039.md) | [(41.4)](/filings/0001070235-25-000132.md) | [(19.7)](/filings/0001070235-25-000176.md) | [(10.5)](/filings/0001070235-25-000198.md) | [(7.4) d](/filings/0001070235-26-000039.md) | [1.9](/filings/0001070235-26-000076.md) | [13.3](/filings/0001070235-26-000115.md) | [13.7](/filings/0001070235-25-000198.md) | [24.3 d](/filings/0001070235-26-000039.md) | [8.5](/filings/0001070235-26-000076.md) | [33.9](/filings/0001070235-26-000115.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001070235-24-000156.md) | not reported | [(0.07)](/filings/0001070235-25-000132.md) | [(0.03)](/filings/0001070235-25-000176.md) | [(0.02)](/filings/0001070235-25-000198.md) | not reported | [0.00](/filings/0001070235-25-000132.md) | [0.02](/filings/0001070235-25-000176.md) | [0.02](/filings/0001070235-25-000198.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.04)](/filings/0001070235-24-000156.md) | not reported | [(0.07)](/filings/0001070235-25-000132.md) | [(0.03)](/filings/0001070235-25-000176.md) | [(0.02)](/filings/0001070235-25-000198.md) | not reported | [0.00](/filings/0001070235-25-000132.md) | [0.02](/filings/0001070235-25-000176.md) | [0.02](/filings/0001070235-25-000198.md) | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-11-30) | FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [210](/filings/0001070235-23-000165.md) | [175](/filings/0001070235-26-000039.md) | [143](/filings/0001070235-24-000095.md) | [171](/filings/0001070235-24-000124.md) | [189](/filings/0001070235-24-000156.md) | [267](/filings/0001070235-26-000039.md) | [276](/filings/0001070235-25-000132.md) | [276](/filings/0001070235-25-000176.md) | [270](/filings/0001070235-25-000198.md) | [275](/filings/0001070235-26-000115.md) | [257](/filings/0001070235-26-000076.md) | [266](/filings/0001070235-26-000115.md) |
| Current assets | $m | [450](/filings/0001070235-23-000165.md) | [508](/filings/0001070235-25-000068.md) | [458](/filings/0001070235-24-000095.md) | [438](/filings/0001070235-24-000124.md) | [455](/filings/0001070235-24-000156.md) | [592](/filings/0001070235-26-000039.md) | [533](/filings/0001070235-25-000132.md) | [507](/filings/0001070235-25-000176.md) | [543](/filings/0001070235-25-000198.md) | [568](/filings/0001070235-26-000115.md) | [560](/filings/0001070235-26-000076.md) | [562](/filings/0001070235-26-000115.md) |
| Total assets | $m | [1,400](/filings/0001070235-23-000165.md) | [1,395](/filings/0001070235-25-000068.md) | [1,323](/filings/0001070235-24-000095.md) | [1,299](/filings/0001070235-24-000124.md) | [1,309](/filings/0001070235-24-000156.md) | [1,296](/filings/0001070235-26-000039.md) | [1,210](/filings/0001070235-25-000132.md) | [1,184](/filings/0001070235-25-000176.md) | [1,218](/filings/0001070235-25-000198.md) | [1,245](/filings/0001070235-26-000115.md) | [1,241](/filings/0001070235-26-000076.md) | [1,263](/filings/0001070235-26-000115.md) |
| Current liabilities | $m | [508](/filings/0001070235-23-000165.md) | [357](/filings/0001070235-25-000068.md) | [321](/filings/0001070235-24-000095.md) | [305](/filings/0001070235-24-000124.md) | [332](/filings/0001070235-24-000156.md) | [344](/filings/0001070235-26-000039.md) | [253](/filings/0001070235-25-000132.md) | [230](/filings/0001070235-25-000176.md) | [253](/filings/0001070235-25-000198.md) | [268](/filings/0001070235-26-000115.md) | [255](/filings/0001070235-26-000076.md) | [237](/filings/0001070235-26-000115.md) |
| Total liabilities | $m | [575](/filings/0001070235-23-000165.md) | [620](/filings/0001070235-25-000068.md) | [581](/filings/0001070235-24-000095.md) | [567](/filings/0001070235-24-000124.md) | [584](/filings/0001070235-24-000156.md) | [576](/filings/0001070235-26-000039.md) | [485](/filings/0001070235-25-000132.md) | [459](/filings/0001070235-25-000176.md) | [477](/filings/0001070235-25-000198.md) | [499](/filings/0001070235-26-000115.md) | [490](/filings/0001070235-26-000076.md) | [471](/filings/0001070235-26-000115.md) |
| Long-term debt | $m | not reported | [194](/filings/0001070235-25-000068.md) | not reported | not reported | not reported | [195](/filings/0001070235-26-000039.md) | [196](/filings/0001070235-25-000132.md) | [196](/filings/0001070235-25-000176.md) | [196](/filings/0001070235-25-000198.md) | [197](/filings/0001070235-26-000115.md) | [197](/filings/0001070235-26-000076.md) | [197](/filings/0001070235-26-000115.md) |
| Shareholders' equity | $m | [825](/filings/0001070235-24-000156.md) | [775](/filings/0001070235-26-000039.md) | [743](/filings/0001070235-25-000176.md) | [732](/filings/0001070235-25-000198.md) | [725](/filings/0001070235-25-000198.md) | [720](/filings/0001070235-26-000115.md) | [725](/filings/0001070235-26-000115.md) | [725](/filings/0001070235-26-000115.md) | [741](/filings/0001070235-25-000198.md) | [746](/filings/0001070235-26-000115.md) | [751](/filings/0001070235-26-000115.md) | [792](/filings/0001070235-26-000115.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-11-30) | Q4 FY2024 (2024-02-29) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q4 FY2025 (2025-02-28) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q4 FY2026 (2026-02-28) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(31.0) d](/filings/0001070235-24-000156.md) | [(15.5) d](/filings/0001070235-26-000039.md) | [(15.1)](/filings/0001070235-25-000132.md) | [(16.0) d](/filings/0001070235-25-000176.md) | [6.0 d](/filings/0001070235-25-000198.md) | [41.6 d](/filings/0001070235-26-000039.md) | [(18.0)](/filings/0001070235-26-000076.md) | [3.9 d](/filings/0001070235-26-000115.md) | [18.3 d](/filings/0001070235-25-000198.md) | [46.1 d](/filings/0001070235-26-000039.md) | [4.6](/filings/0001070235-26-000076.md) | [29.3 d](/filings/0001070235-26-000115.md) |
| Capital expenditure | $m | [2.0 d](/filings/0001070235-24-000156.md) | [2.1 d](/filings/0001070235-26-000039.md) | [1.4](/filings/0001070235-25-000132.md) | [0.5 d](/filings/0001070235-25-000176.md) | [0.8 d](/filings/0001070235-25-000198.md) | [0.4 d](/filings/0001070235-26-000039.md) | [0.9](/filings/0001070235-26-000076.md) | [0.8 d](/filings/0001070235-26-000115.md) | [0.9 d](/filings/0001070235-25-000198.md) | [1.2 d](/filings/0001070235-26-000039.md) | [2.9](/filings/0001070235-26-000076.md) | [1.2 d](/filings/0001070235-26-000115.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001070235-25-000132.md) | [0.0 d](/filings/0001070235-25-000176.md) | [0.0 d](/filings/0001070235-25-000198.md) | [0.0 d](/filings/0001070235-26-000039.md) | [10.0](/filings/0001070235-26-000076.md) | [20.0](/filings/0001070235-26-000115.md) | [4.0](/filings/0001070235-25-000198.md) | [26.7 d](/filings/0001070235-26-000039.md) | [10.0](/filings/0001070235-26-000076.md) | [0.0 d](/filings/0001070235-26-000115.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-11-30) | Q1 FY2024 (2023-05-31) | Q2 FY2024 (2023-08-31) | Q3 FY2024 (2023-11-30) | Q1 FY2025 (2024-05-31) | Q2 FY2025 (2024-08-31) | Q3 FY2025 (2024-11-30) | Q1 FY2026 (2025-05-31) | Q2 FY2026 (2025-08-31) | Q3 FY2026 (2025-11-30) | Q1 FY2027 (2026-05-31) | Q2 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [640](/filings/0001070235-23-000165.md) | [583](/filings/0001070235-23-000111.md) | [584](/filings/0001070235-23-000131.md) | [638](/filings/0001070235-24-000156.md) | [590](/filings/0001070235-25-000132.md) | [592](/filings/0001070235-25-000176.md) | [594](/filings/0001070235-25-000198.md) | [601](/filings/0001070235-26-000076.md) | [597](/filings/0001070235-26-000115.md) | [596](/filings/0001070235-25-000198.md) | [593](/filings/0001070235-26-000076.md) | [650](/filings/0001070235-26-000115.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 587,032,279 at 2026-09-21, from the cover of the [10-Q filed 2026-09-24](/filings/0001070235-26-000115.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.